NUWE

Nuwellis Inc

Add to Watchlist

Advanced Chart

11.290

-0.83(-6.848%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

11.980

Open

11.560

VWAP

Vol

172.23K

Mkt Cap

5.95M

Low

10.910

Amount

EV/EBITDA(TTM)

Total Shares

18.05M

3.84M

EV/OCF(TTM)

P/S(TTM)

3.28

Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

2.52M

+8.7%

2.50M

+5.62%

2.20M

+0.27%

Estimates Revision

The market is revising Downward the revenue expectations for Nuwellis, Inc. (NUWE) for FY2025, with the revenue forecasts being adjusted by -15.99% over the past three months. During the same period, the stock price has changed by -73.12%.

Revenue Estimates for FY2025

Revise Downward

-15.99%

In Past 3 Month

Stock Price

Go Down

-73.12%

In Past 3 Month

1 Analyst Rating

-2.57% Downside

Wall Street analysts forecast NUWE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUWE is 11.00 USD with a low forecast of 11.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

-2.57% Downside

Current: 11.290

Low

11.00

Averages

11.00

High

11.00

-2.57% Downside

Current: 11.290

Low

11.00

Averages

11.00

High

11.00

Roth Capital

Jonathan Aschoff

Buy

downgrade

$13 -> $11

2025-05-13

Reason

Roth Capital

Jonathan Aschoff

Price Target

$13 -> $11

2025-05-13

downgrade

Buy

Reason

Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Nuwellis to $11 from $13 and keeps a Buy rating on the shares. While the company's Q1 revenue was down 18% quarter over quarter, pediatric utilization grew 38% year over year, the analyst tells investors in a research note. The firm believes that the four-fold increase in Aquadex Centers for Medicare & Medicaid Services reimbursement should support future revenue growth.

Roth MKM

Jonathan Aschoff

Strong Buy

Reiterates

$17

2024-08-13

Reason

Roth MKM

Jonathan Aschoff

Price Target

$17

2024-08-13

Reiterates

Strong Buy

Reason

Roth MKM

Jonathan Aschoff

Strong Buy

Initiates

$17

2024-07-29

Reason

Roth MKM

Jonathan Aschoff

Price Target

$17

2024-07-29

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Nuwellis Inc (NUWE.O) is -0.17, compared to its 5-year average forward P/E of -0.84. For a more detailed relative valuation and DCF analysis to assess Nuwellis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.84

Current PE

-0.17

Overvalued PE

-0.16

Undervalued PE

-1.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.77

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

26.21

Undervalued EV/EBITDA

-37.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.06

Current PS

0.13

Overvalued PS

2.03

Undervalued PS

0.08